^
Association details:
| Biomarker: | ALK mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase II trial of dasatinib in advanced melanoma
Excerpt:
On the basis of our pre-clinical data, we identified a patient with ALKATI-expressing metastatic melanoma (Fig. 4f, g)… Subsequent treatment with crizotinib resulted in marked symptomatic improvement and tumour shrinkage within 6 weeks of therapy (Fig. 4h).
DOI:
10.1038/nature15258
